Tetrahedron Letters 51 (2010) 4882–4885

Contents lists available at ScienceDirect

Tetrahedron Letters

journal homepage: www.elsevier.com/locate/tetlet

Synthetic studies of mycalolide B, an actin-depolymerizing marine macrolide: construction of the tris-oxazole macrolactone using ring-closing metathesis

Masaki Kita, Hidekazu Watanabe, Tomoya Ishitsuka, Yuzo Mogi, Hideo Kigoshi *

Department of Chemistry, Graduate School of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8571, Japan

ARTICLE INFO

Article history:
Received 9 June 2010
Revised 7 July 2010
Accepted 9 July 2010
Available online 13 July 2010

Keywords:
Actin-depolymerizing compound
Ring-closing metathesis
Tris-oxazole macrolide
Synthesis of marine natural products

ABSTRACT

Tris-oxazole macrolactone **2**, a key intermediate of mycalolide B (**1**), which has 13 stereogenic centres, was synthesized through the use of ring-closing metathesis (RCM). The *E*/*Z* ratio of the RCM product **2** was reversed by the use of CH_2Cl_2 and toluene, whereas a cross-metathesis reaction yielded the C1–C35 long-chain compound **19** in a highly *E*-selective manner. Thus, the loss of flexibility in aliphatic carbon chains and the steric hinderance of β- and γ-substituents of the C20 olefin in the precursor **11** may affect the stereoselectivity in RCM reactions.

Mycalolide B (**1**) is a cytotoxic and antifungal macrolide isolated from the marine sponge *Mycale* sp. It bears a unique tris-oxazole structure and has 13 stereogenic centers (Fig. 1).[1] This compound also inhibits actomyosin Mg^{2+}–ATPase and shows potent actin-depolymerizing activity by sequestering G-actin and forming a 1:1 complex.[2] Mycalolides can be divided into two characteristic parts: the C1–C24 macrolactone and the C25–C35 side-chain moieties. Studies of the structure–activity relationship[3] and photoaffinity labeling experiments[4] have established that the side-chain part of **1** is critically important for its ability to bind to and depolymerize actin. Several tris-oxazole macrolides closely related to mycalolides have been isolated, such as ulapualides,[5] halichondramides,[6] jaspisamides,[7] and kabiramides;[8] all of which exhibit potent actin-depolymerizing properties. These agents may be useful for the development of novel pharmacological tools for analyzing actin-mediated cell functions, such as muscle contraction, cell motility, and cytokinesis. Furthermore, it is noteworthy that aplyronine A, which has an actin-binding side-chain moiety similar to mycalolides, exhibits potent antitumor activity in vivo against P388 leukemia and several cancers.[9,10] Thus, mycalolides and related actin-targeting natural products have great potential as preclinical candidates for use in cancer chemotherapy.

Due to their extraordinary structures and important biological activities, several synthetic studies on tris-oxazole-containing macrolides have been reported.[11] Recently, total syntheses of mycalolide A[12] and ulapualide A[13] have been accomplished, in which Yamaguchi lactonization, cyclization of the central oxazole ring, or intramolecular Horner–Wadsworth–Emmons olefination



Mycalolide B (**1**)



2

Figure 1.

* Corresponding author. Tel./fax: +81 29 853 4313.
E-mail address: kigoshi@chem.tsukuba.ac.jp (H. Kigoshi).

0040-4039/$ - see front matter © 2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2010.07.046

were used to construct macrocycles. Subsequent studies have shown that olefin metathesis is a useful method for connecting the C19–C20 double bonds in mycalolide analogs.[14] Here we describe the synthesis of tris-oxazole macrolactone **2**, a key synthetic intermediate of mycalolides, through the use of ring-closing metathesis (RCM). We expected that the convergent assembly of three fragments via Ni/Cr-mediated Nozaki–Hiyama–Kishi coupling[15] at C6–C7, esterification, and RCM at the C19–C20 olefin could efficiently afford **2**.

The synthesis started with removal of the Boc and acetonide groups of the previously reported oxazole (−)-**3**[14] under acidic conditions, and subsequent condensation with 2-chlorooxazole-4-carboxylic acid[16] afforded amide **4** (77%, two steps) (Scheme 1). Due to the considerable instability of the 2-vinyloxazole moieties under basic and dehydration conditions, we planned to introduce the vinyl group into the oxazole ring after construction of the tris-oxazole structure. Dehydrating cyclization of **4** by diethylaminosulfur trifluoride (DAST)[17] gave an oxazoline intermediate (85%), which was oxidized with a combination of bromotrichloromethane and 1,8-diazabicycloundec-7-ene (DBU)[18] at room temperature to give tris-oxazole **5** (98% based on recovered starting material).[19] We found that acetonitrile is a better solvent than the conventional CH_2Cl_2 in this reaction. Catalytic dihydroxylation of **5** with OsO_4–NMO and Migita–Stille coupling with tri-*n*-butylvinyltin furnished a vinyloxazole intermediate, and this was transformed into aldehyde **6** via oxidative cleavage of the 1,2-diol with $NaIO_4$ (73%, three steps).



Scheme 1. Synthesis of the RCM precursor **11**. Reagents and conditions: (a) 3 M HCl, EtOAc, rt; (b) 2-chlorooxazole-4-carboxylic acid, EDCI·HCl, HOBt, Et_3N, CH_2Cl_2, 0 °C to rt, 77% in two steps; (c) DAST, CH_2Cl_2, −78 to 0 °C, 85%; (d) DBU, $BrCCl_3$, MeCN, rt, 54% (98% br s m); (e) OsO_4, NMO, THF–^{t}BuOH–H_2O, rt; (f) tri-*n*-butylvinyltin, $PdCl_2(PPh_3)_2$, 1,4-dioxane, reflux; (g) $NaIO_4$, EtOH–H_2O, rt, 73% in three steps; (h) **7**, $CrCl_2$–$NiCl_2$, THF–DMF, rt; (i) DMP, pyridine, CH_2Cl_2, rt, 71% in two steps; (j) TFA, CH_2Cl_2, 0 °C, 90%; (k) TBAF, THF, 40 °C, 97%; (l) **10**, MNBA, Et_3N, DMAP, CH_2Cl_2, rt, 55%.

Fragment coupling between **6** and vinyl iodide **7**[12] by a Ni/Cr-mediated coupling reaction was followed by oxidation of the C7 allylic alcohol with Dess–Martin periodinane (DMP)[20] to afford a ketone (71%, two steps), the *tert*-butyl group of which was removed to give carboxylic acid **8** (90%). Removal of the *tert*-butyldimethylsilyl (TBS) group in **9**[14,3b,21] by tetra-*n*-butylammonium fluoride (TBAF) gave C20–C35 fragment **10** (97%), which was condensed with **8** by the Shiina procedure[22] to afford the RCM precursor **11** in 55% yield.

With the key intermediate **11** in hand, RCM reactions were examined (Table 1). First, treatment of **11** with 30 mol % of 2nd-generation Grubbs catalyst (**12**)[23] in degassed refluxing toluene led to the decomposition of the starting material and gave a complex mixture (entry 1). We assumed that the low reactivity of **11** toward RCM reactions would be due to the electron-deficient C19 olefin. To overcome this problem, a more thermally-stable and highly-active catalyst was considered. Treatment of **11** with 30 mol % of 2nd-generation Hoveyda–Grubbs catalyst (**13**)[24] in refluxing CH_2Cl_2 (0.8 mM) yielded tris-oxazole lactone **2** as a separable 2:1 mixture of stereoisomers in 30% yield (entry 2).[25–27] With the use of toluene as a solvent (0.9 mM), the yield of **2** was improved to 76%, but the *E*/*Z*-product ratio was changed to 1:1.2 (entry 3).

For comparison, we also used a cross-metathesis reaction (Scheme 2). Acidic treatment of cyanide **15** in aqueous MeOH, which was prepared from (*S*)-epichlorohydrin (**14**),[28] and protection of the hydroxyl group gave **16** (60% in two steps). Ozonolysis of the terminal olefin (80%) and Takai olefination[29] gave vinyl iodide **17** (66%, *E*/*Z* = 11:1). Nozaki–Hiyama–Kishi coupling between compounds **6** and **17** gave an allylic alcohol (87%), which was oxidized with DMP to afford the C1–C19 ketone **18** in 84% yield. In contrast to the RCM reactions, treatment of the C1–C19 segment **18** (1.2 equiv) and the C20–C35 segment **9** with 50 mol % of catalyst **13** in refluxing CH_2Cl_2 (7 mM for **9**) for 25 h yielded the C1–C35 long-chain compound **19** in a highly *E*-selective manner (66%, *E*/*Z* = 5:1).[25,30–32]

Our work demonstrated that the RCM reaction of **11** proceeded with low stereoselectivity, unlike the cross-metathesis reaction of

Table 1
Ring-closing metathesis of **11**



Entry	Catalyst (30 mol %)	Reaction conditions	Yields (%)	
			Product	19*Z*-isomer
1	**12**	Toluene, reflux, 4 h	Trace [a]	Trace
2	**13**	CH_2Cl_2, reflux, 24 h	20 [b]	10
3	**13**	Toluene, reflux, 3 h	34	42

[a] S.m. was decomposed and not recovered.
[b] S.m. was recovered (50%).



Scheme 2. Cross-metathesis reaction. Reagents and conditions: (a) concd H_2SO_4, MeOH–H_2O, reflux; (b) TBDPSCl, imidazole, DMF, rt, 60% in two steps; (c) O_3, CH_2Cl_2, −78 °C, then Me_2S, −78 °C to rt, 80%; (d) $CrCl_2$, CHI_3, 1,4-dioxane–THF, rt, 65%; (e) **17**, $CrCl_2$–$NiCl_2$, THF–DMF, rt, 87%; (f) DMP, pyridine, CH_2Cl_2, rt, 84%; (g) **9**, **13** (50 mol %), CH_2Cl_2, reflux, 55% with 11% of 19*Z*-isomer.

18. The *E*/*Z* ratios did not significantly change during the course of the metathesis reactions, and thus the formation of C=C bonds in **2** and **19** would take place under kinetic control. In the ruthenocyclobutane intermediate for the desired 19*E*-isomer of **2**, the oxazole rings and the C21–C35 alkyl chain are located in an *anti*-orientation. Due to the rigidness of the tris-oxazole and α,β-unsaturated ketone moieties, the *anti*-ruthenocyclobutane intermediate would be more strained than the *syn*-intermediate, which may affect the stereoselectivity in RCM reactions.

In conclusion, we achieved the synthesis of tris-oxazole macrolactone **2** through the use of RCM reactions as a key step, which includes all of the 13 stereogenic centers and the whole carbon framework of mycalolide B (**1**). Also, this key intermediate possesses a common framework for mycalolides and related actin-depolymerizing tris-oxazole macrolides. Studies on the total synthesis of mycalolide B (**1**) as well as on the stereoselectivity of RCM reactions, especially solvent effects, are currently underway.

Acknowledgments

Support was provided by JSPS via Grants-in-Aids for Scientific Research (21681028 and 21651091 for M.K., and 20310129 for H.K.), by the Kato Memorial Bioscience Foundation, and by the Uehara Memorial Foundation.

References and notes

1. (a) Fusetani, N.; Yasumuro, K.; Matsunaga, S.; Hashimoto, K. *Tetrahedron Lett.* **1989**, *30*, 2809; (b) Matsunaga, S.; Liu, P.; Celatka, C. A.; Panek, J. S.; Fusetani, N. *J. Am. Chem. Soc.* **1999**, *121*, 5605.
2. (a) Hori, M.; Saito, S.; Shin, Y.; Ozaki, H.; Fusetani, N.; Karaki, H. *FEBS Lett.* **1993**, *322*, 151; (b) Saito, S.; Watabe, S.; Ozaki, H.; Fusetani, N.; Karaki, H. *J. Biol. Chem.* **1994**, *269*, 29710.
3. (a) Suenaga, K.; Miya, S.; Kuroda, T.; Handa, T.; Kanematsu, K.; Sakakura, A.; Kigoshi, H. *Tetrahedron Lett.* **2004**, *45*, 5383; (b) Suenaga, K.; Kimura, T.; Kuroda, T.; Matsui, K.; Miya, S.; Kuribayashi, S.; Sakakura, A.; Kigoshi, H. *Tetrahedron* **2006**, *62*, 8278.
4. Kuroda, T.; Suenaga, K.; Sakakura, A.; Handa, T.; Okamoto, K.; Kigoshi, H. *Bioconjugate Chem.* **2006**, *17*, 524.
5. Roesener, J. A.; Scheuer, P. J. *J. Am. Chem. Soc.* **1986**, *108*, 846.
6. (a) Matsunaga, S.; Fusetani, N.; Hashimoto, K.; Koseki, K.; Noma, M.; Noguchi, H.; Sankawa, U. *J. Org. Chem.* **1989**, *54*, 1360; (b) Kernan, M. R.; Molinski, T. F.; Faulkner, D. J. *J. Org. Chem.* **1988**, *53*, 5014.
7. Kobayashi, J.; Murata, O.; Shigemori, H. *J. Nat. Prod.* **1993**, *56*, 787.
8. (a) Matsunaga, S.; Fusetani, N.; Hashimoto, K. *J. Am. Chem. Soc.* **1986**, *108*, 847; (b) Tanaka, J.; Yan, Y.; Choi, J.; Bai, J.; Klenchin, V. A.; Rayment, I.; Marriott, G. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 13851; (c) Klenchin, V. A.; Allingham, J. S.; King, R.; Tanaka, J.; Marriott, G.; Rayment, I. *Nat. Struct. Biol.* **2003**, *10*, 1058.
9. (a) Yamada, K.; Ojika, M.; Ishigaki, T.; Yoshida, Y.; Ekimoto, H.; Arakawa, M. *J. Am. Chem. Soc.* **1993**, *115*, 11020; (b) Ojika, M.; Kigoshi, H.; Ishigaki, T.; Tsuboi, T.; Ogawa, T.; Yamada, K. *J. Am. Chem. Soc.* **1994**, *116*, 7441; (c) Kigoshi, H.; Suenaga, K.; Mutou, T.; Ishigaki, T.; Atsumi, T.; Ishiwata, H.; Sakakura, A.; Ogawa, T.; Ojika, M.; Yamada, K. *J. Org. Chem.* **1996**, *61*, 5326; (d) Hirata, K.; Muraoka, S.; Suenaga, K.; Kuroda, T.; Kato, K.; Tanaka, H.; Yamamoto, M.; Takata, M.; Yamada, K.; Kigoshi, H. *J. Mol. Biol.* **2006**, *356*, 945.
10. Reviews: (a) Ojika, M.; Kigoshi, H.; Yoshida, Y.; Ishigaki, T.; Nisiwaki, M.; Tsukada, I.; Arakawa, M.; Ekimoto, H.; Yamada, K. *Tetrahedron* **2007**, *63*, 3138; (b) Yamada, K.; Ojika, M.; Kigoshi, H.; Suenaga, K. *Nat. Prod. Rep.* **2009**, *26*, 27.
11. Reviews: (a) Yeung, K.-S.; Paterson, I. *Angew. Chem., Int. Ed.* **2002**, *41*, 4632; (b) Chattopadhyay, S. K.; Pattenden, G. *J. Chem. Soc., Perkin Trans. 1* **2000**, 2429. and references are therein.
12. (a) Liu, P.; Panek, J. S. *J. Am. Chem. Soc.* **2000**, *122*, 1235; (b) Panek, J. S.; Liu, P. *J. Am. Chem. Soc.* **2000**, *122*, 11090.
13. (a) Pattenden, G.; Ashweek, N. J.; Baker-Glenn, C. A. G.; Walker, G. M.; Yee, J. G. K. *Angew. Chem., Int. Ed.* **2007**, *46*, 4359; (b) Chattopadhyay, S. K.; Pattenden, G. *Tetrahedron Lett.* **1998**, *39*, 6095.
14. Kimura, T.; Kuribayashi, S.; Sengoku, T.; Matsui, K.; Ueda, S.; Hayakawa, I.; Suenaga, K.; Kigoshi, H. *Chem. Lett.* **2007**, *36*, 1490.
15. (a) Jin, H.; Uenishi, J.; Christ, W. J.; Kishi, Y. *J. Am. Chem. Soc.* **1986**, *108*, 5644; (b) Takai, K.; Tagashira, M.; Kuroda, T.; Oshima, K.; Utimoto, K.; Nozaki, H. *J. Am. Chem. Soc.* **1986**, *108*, 6048; (c) Okude, Y.; Hirano, S.; Hiyama, T.; Nozaki, H. *J. Am. Chem. Soc.* **1977**, *99*, 3179.
16. (a) Young, G. L.; Smith, S. A.; Taylor, R. J. K. *Tetrahedron Lett.* **2004**, *45*, 3797; (b) Grank, G.; Fouris, M. J. *J. Med. Chem.* **1971**, *14*, 1075.
17. Phillips, A. J.; Uto, Y.; Wipf, P.; Reno, M. J.; Williams, D. R. *Org. Lett.* **2000**, *2*, 1165.
18. Williams, D. R.; Lowder, P. D.; Gu, Y.-G.; Brooks, D. A. *Tetrahedron Lett.* **1997**, *38*, 331.
19. NiO_2 oxidation of oxazoline intermediate also afforded **8**, but a low yield (~30%) and significant loss of starting material recovery, probably due to the strong coordination of bis- or tris-oxazole nitrogen atoms to nickel atom.
20. Dess, D. B.; Martin, J. C. *J. Am. Chem. Soc.* **1991**, *113*, 7277.
21. Although configuration of the C35 acetal carbon in **9** has not been determined, **9** is a single stereoisomer. See Ref. 3b.
22. (a) Shiina, I.; Kubota, M.; Ibuka, R. *Tetrahedron Lett.* **2002**, *43*, 7535; (b) Shiina, I.; Kubota, M.; Oshiumi, H.; Hashizume, M. *J. Org. Chem.* **2004**, *69*, 1822.
23. (a) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. *Org. Lett.* **1999**, *1*, 953; (b) Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H. *J. Am. Chem. Soc.* **2003**, *125*, 11360.
24. (a) Kingsbury, J. S.; Harrity, J. P. A.; Bonitatebus, P. J.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1999**, *121*, 791; (b) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2000**, *122*, 8168.
25. The stereochemistry of the C19 olefins in **2** and **19** was established based on $^3J_{H19,H20}$ values (15.8 and 15.9 Hz). In contrast, the $^3J_{H19,H20}$ values of 19*Z*-**2** and 19*Z*-**19** were 11.4 and 11.3 Hz, respectively.
26. *Spectral data for* **2**: R_f 0.12 (hexane/EtOAc = 1:1); $[\alpha]_D^{24}$ −26.2 (*c* 0.030, $CHCl_3$); ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.11 (s, 1H, H-14), 8.06 (s 1H, H-17), 7.71–7.67 (m, 4H, –Si(t-Bu)*Ph*$_2$), 7.66 (s, 1H, H-11), 7.42–7.34 (m, 6H, –Si(t-Bu)*Ph*$_2$), 7.15–7.06 (m, 2H, H-5, H-20), 6.90–6.80 (m, 3H, –C_6H_3(OMe)$_2$), 6.32 (d, *J* = 15.8 Hz, 1H, H-19), 5.90 (d, *J* = 16.2 Hz, 1H, H-6), 5.12 (m, 1H, H-24), 4.86 (d, *J* = 4.7 Hz, 1H, H-35), 4.81–4.79 (AB quart, *J* = 11.2 Hz, 2H, –OC*H*$_2$O–), 4.56 (s, 2H, –OC*H*$_2$Ar), 4.43 (m, 1H, H-22), 4.37 (d, *J* = 9.5 Hz, 1H, H-9), 4.28 (m, 1H, H-3), 4.19 (m, 1H, H-26), 4.02 (m, 1H, H-30), 3.87 (s, 3H, –O*Me*), 3.86 (s, 3H, –O*Me*), 3.54 (m, 1H, H-32), 3.26 (s, 3H, –O*Me*), 3.24 (s, 3H, –O*Me*), 3.22 (s, 3H, –O*Me*), 3.10 (s, 3H, –O*Me*), 2.98 (m, 1H), 2.74–2.70 (m, 2H), 2.45–2.28 (m, 2H), 1.80 (m, 4H), 1.66–1.40 (m, 10H), 1.08 (d, *J* = 6.6 Hz, 3H), 1.03 (s, 9H, –Si(t-*Bu*)Ph$_2$), 0.88–0.77 (m, 12H); IR ($CHCl_3$) 2930, 1733, 1654, 1516, 1458, 1381, 1262, 1106, 1027, 755, 704 cm^{-1}; HRMS (ESI) *m*/*z* 1282.6232 (calcd for $C_{70}H_{93}N_3NaO_{18}Si$ [M+Na]$^+$, Δ +1.0 mmu).
27. The dimer of **11** was not formed.
28. Hanazawa, T.; Okamoto, T.; Sato, F. *Tetrahedron Lett.* **2001**, *42*, 5455.
29. (a) Takai, K.; Nitta, K.; Utimoto, K. *J. Am. Chem. Soc.* **1986**, *108*, 7408; (b) Takai, K.; Kimura, K.; Kuroda, T.; Hiyama, T.; Nozaki, H. *Tetrahedron Lett.* **1983**, *24*, 5281.
30. *Spectral data for* **19**: R_f 0.10 (hexane/EtOAc = 1:1); $[\alpha]_D^{25}$ −15.5 (*c* 0.415, $CHCl_3$); ^{1}H NMR (270 MHz, $CDCl_3$) δ 8.33 (s, 1H, H-14), 8.28 (s, 1H, H-17), 7.69 (s, 1H, H-11), 7.69–7.64 (m, 4H, –Si(t-Bu)*Ph*$_2$), 7.42–7.36 (m, 6H, –Si(t-Bu)*Ph*$_2$), 6.93–6.75 (m, 5H, H-5, H-20, –C_6H_3(OMe)$_2$), 6.44 (d, *J* = 15.9 Hz, 1H, H-19), 6.11 (d, *J* = 15.7 Hz, 1H, H-6), 4.89 (d, *J* = 4.9 Hz, 1H, H-35), 4.83 (s, 2H, –OC*H*$_2$O–), 4.59 (s, 2H, –OC*H*$_2$Ar), 4.39 (d, *J* = 10.0 Hz, 1H, H-9), 4.32 (m, 1H, H-3), 4.07 (m, 1H, H-30), 3.92 (m, 1H, H-24), 3.89 (s, 3H, –O*Me*), 3.87 (s, 3H, –O*Me*), 3.58 (dd,

J = 6.8, 9.5 Hz, 1H, H-22), 3.56 (s, 3H, –O*Me*), 3.44 (m, 1H, H-32), 3.36 (s, 3H, –O*Me*), 3.33 (s, 3H, –O*Me*), 3.29 (s, 3H, –O*Me*), 3.20 (m, 1H, H-26), 3.17 (s, 3H, –O*Me*), 3.03 (m, 1H), 2.60 (m, 1H), 2.53–2.39 (m, 5H), 2.30–2.05 (m, 3H), 1.87 –1.73 (m, 2H), 1.69–1.12 (m, 7H), 1.11 (d, *J* = 6.5 Hz, 3H), 1.04 (s, 9H, –Si(*t Bu*)Ph_2), 0.95 (d, *J* = 6.8 Hz, 3H), 0.89 (d, *J* = 7.6 Hz, 3H), 0.87–0.82 (m, 6H), 0.84 (s, 9H, –Si(*t Bu*)Me_2), 0.00 (s, 3H, –Si(*t*Bu)*Me*$_2$), −0.06 (s, 3H, –Si(*t*Bu)*Me*$_2$); ^{13}C NMR (150 MHz, $CDCl_3$) δ 201.8, 171.4, 161.9, 156.1, 155.5, 148.9, 148.5, 142.7, 139.8, 138.6 (2C), 138.5, 137.2, 135.9 (2C), 135.8 (2C), 133.4 (2C), 132.9, 131.5, 130.7, 130.5, 129.9, 129.8, 127.7 (2C), 127.6 (2C), 120.5, 118.0, 111.3, 110.8, 104.6, 94.4, 87.1, 82.5, 82.1, 78.4, 77.5, 69.6, 69.4, 69.2, 57.6, 57.2, 56.9, 55.9, 55.8, 54.5, 51.5, 46.9, 43.4, 43.1, 42.5, 41.5, 40.2, 35.9, 34.6, 33.7, 32.6, 30.6, 26.9, 26.9, 26.9, 26.8, 25.8, 25.8, 25.8, 20.1, 19.2, 18.0, 15.8, 14.1, 9.2, 8.8, −4.1, −4.7; IR ($CHCl_3$) 1733, 1664, 1517, 1464, 1380, 1260, 1096, 1029, 919, 823 cm^{-1}; HRMS (ESI) *m*/*z* 725.8638 (calcd for $(C_{77}H_{111}N_3Na_2O_{17}Si_2)/2$ $[M+2Na]^{2+}$, Δ +1.4 mmu).

31. The C20–C35 dimer was afforded in 15% yield, and the dimer of **18** was not formed.
32. Model reactions for the cross-metathesis of 2-vinyloxazole derivatives using catalyst **13** in toluene at 40 °C also preferentially yielded *E*-isomer, but the selectivity was lower than in the case of CH_2Cl_2 (*E*/*Z* = 2.0–1.5:1). Thus, the difference of solvent (CH_2Cl_2 and toluene) rather than reaction temperature may affect the stereoselectivity in the RCM reactions of **11**.